{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:52:44Z","timestamp":1740174764807,"version":"3.37.3"},"reference-count":92,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":706,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A strong association exists between epilepsy and psychiatric comorbidities, especially depression, anxiety, attention deficit disorders, and psychosis. The impact of psychotropic medications in lowering seizure threshold both directly and indirectly, hypersensitivity reactions to antiepileptic and other psychotropic medications, and how antiepileptic drugs affect psychiatric disorders are explored through three patient cases. Ultimately, in selecting an appropriate psychotropic medication for an individual with epilepsy and psychiatric comorbidities, it is important to consider the clinical and quality-of-life impacts that a particular medication will have on that individual.<\/jats:p>","DOI":"10.9740\/mhc.2017.11.235","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T14:56:17Z","timestamp":1509548177000},"page":"235-245","source":"Crossref","is-referenced-by-count":4,"title":["Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-7298","authenticated-orcid":false,"given":"Kimberly","family":"Tallian","sequence":"first","affiliation":[{"name":"(Corresponding author) Advanced Practice Pharmacist \u2013 Psychiatry and PGY2 Residency Program Director, Psychiatry, Scripps Mercy Hospital, San Diego, California; Adjunct Clinical Professor \u2013 University of California, San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences, San Diego, California, kim.tallian@yahoo.com"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"45","key":"2020060307343868100_i2168-9709-7-6-235-b01","first-page":"909","article-title":"Epilepsy in adults and access to care \u2014 United States, 2012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b02","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1542\/peds.2010-1371","article-title":"A national profile of childhood epilepsy and seizure disorder","volume":"129","author":"Russ","year":"2012","journal-title":"Pediatrics"},{"issue":"9226","key":"2020060307343868100_i2168-9709-7-6-235-b03","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0140-6736(00)02515-0","article-title":"Management of epilepsy in adolescents and adults","volume":"356","author":"Brodie","year":"2000","journal-title":"Lancet"},{"key":"2020060307343868100_i2168-9709-7-6-235-b04","unstructured":"Institute of Medicine (US). Committee on the Public Health Dimensions of the Epilepsies; England MJ, Liverman CT, Schultz AM, Strawbridge LM, editors. Epilepsy across the spectrum: Promoting health and understanding. Washington: National Academies Press;2012."},{"issue":"6","key":"2020060307343868100_i2168-9709-7-6-235-b05","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/14740338.2011.588597","article-title":"Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications","volume":"10","author":"Hamed","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b06","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/ana.23601","article-title":"Epilepsy, suicidality, and psychiatric disorders: a bidirectional association","volume":"72","author":"Hesdorffer","year":"2012","journal-title":"Ann Neurol"},{"issue":"11","key":"2020060307343868100_i2168-9709-7-6-235-b07","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/j.1528-1167.2011.03268.x","article-title":"Bidirectional relation between schizophrenia and epilepsy: a population-based retrospective cohort study","volume":"52","author":"Chang","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"2020060307343868100_i2168-9709-7-6-235-b08","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1212\/01.WNL.0000058907.41080.54","article-title":"Comorbidity of migraine and depression: investigating potential etiology and prognosis","volume":"60","author":"Breslau","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"2020060307343868100_i2168-9709-7-6-235-b09","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/hs0901.094623","article-title":"Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study","volume":"32","author":"Larson","year":"2001","journal-title":"Stroke"},{"key":"2020060307343868100_i2168-9709-7-6-235-b10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12974-015-0266-z","article-title":"Mesial temporal lobe epilepsy with psychiatric comorbidities: a place for differential neuroinflammatory interplay","volume":"12","author":"Kandratavicius","year":"2015","journal-title":"J Neuroinflammation"},{"issue":"12","key":"2020060307343868100_i2168-9709-7-6-235-b11","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1111\/j.1528-1167.2007.01230.x","article-title":"Interictal psychoses in comparison with schizophrenia--a prospective study","volume":"48","author":"Tadokoro","year":"2007","journal-title":"Epilepsia"},{"issue":"12","key":"2020060307343868100_i2168-9709-7-6-235-b12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/j.0013-9580.2004.17504.x","article-title":"The epidemiology of the comorbidity of epilepsy in the general population","volume":"45","author":"Gaitatzis","year":"2004","journal-title":"Epilepsia"},{"key":"2020060307343868100_i2168-9709-7-6-235-b13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/CBO9780511977145.002","article-title":"Neuropsychiatric disorders in epilepsy: epidemiology and classification","author":"Hesdorffer","year":"2011","journal-title":"Neuropsychiatric disorders in epilepsy: epidemiology and classification"},{"issue":"12","key":"2020060307343868100_i2168-9709-7-6-235-b14","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric comorbidity in epilepsy: a population-based analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yebeh.2005.05.014","article-title":"Anxiety in patients with epilepsy: systematic review and suggestions for clinical management","volume":"7","author":"Beyenburg","year":"2005","journal-title":"Epilepsy Behav"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.seizure.2009.11.005","article-title":"Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database","volume":"19","author":"Kumlien","year":"2010","journal-title":"Seizure"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1517\/14740338.2.3.233","article-title":"Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings","volume":"2","author":"Lee","year":"2003","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/14737175.6.4.575","article-title":"Epileptogenic drugs: a systematic review","volume":"6","author":"Ruffmann","year":"2006","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.psc.2013.02.004","article-title":"Antidepressant overdose-induced seizures","volume":"36","author":"Judge","year":"2013","journal-title":"Psychiatr Clin North Am"},{"author":"Activas Pharma, Inc","key":"2020060307343868100_i2168-9709-7-6-235-b20","article-title":"Amoxapine tablet"},{"author":"Mallinckrodt, Inc","key":"2020060307343868100_i2168-9709-7-6-235-b21","article-title":"Clomipramine Hydrochloride capsule"},{"author":"Mylan Pharmaceuticals, Inc","key":"2020060307343868100_i2168-9709-7-6-235-b22","article-title":"Maprotiline Hydrochloride tablet, film coated"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120037428","article-title":"Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose","volume":"42","author":"Isbister","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","article-title":"Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports","volume":"62","author":"Alper","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"11","key":"2020060307343868100_i2168-9709-7-6-235-b25","first-page":"450","article-title":"A 102-center prospective study of seizure in association with bupropion","volume":"52","author":"Johnston","year":"1991","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"},{"author":"Heritage Pharmaceuticals Inc","key":"2020060307343868100_i2168-9709-7-6-235-b27","article-title":"Bupropion Hydrochloride tablet"},{"author":"Sandoz Inc","key":"2020060307343868100_i2168-9709-7-6-235-b28","article-title":"Chlorpromazine Hydrochloride tablet, sugar coated"},{"author":"Major Pharmaceuticals","key":"2020060307343868100_i2168-9709-7-6-235-b29","article-title":"Haloperidol tablet"},{"author":"Mylan Pharmaceuticals Inc","key":"2020060307343868100_i2168-9709-7-6-235-b30","article-title":"Clozapine tablet"},{"author":"Teva Pharmaceuticals USA, Inc","key":"2020060307343868100_i2168-9709-7-6-235-b31","article-title":"Olanzapine tablet, film coated"},{"author":"Jubilant Cadista Pharmaceuticals Inc","key":"2020060307343868100_i2168-9709-7-6-235-b32","article-title":"Quetiapine Fumerate tablet"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1469-8749.2007.00498.x","article-title":"Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine","volume":"49","author":"Wernicke","year":"2007","journal-title":"Dev Med Child Neurol"},{"author":"UCB Pharma Inc","key":"2020060307343868100_i2168-9709-7-6-235-b34","article-title":"Methylphenidate Hydrochloride tablet"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00406-011-0208-4","article-title":"EEG alterations during treatment with olanzapine","volume":"261","author":"Degner","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1176\/appi.ajp.159.1.109","article-title":"EEG abnormalities during treatment with typical and atypical antipsychotics","volume":"159","author":"Centorrino","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"12","key":"2020060307343868100_i2168-9709-7-6-235-b37","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/WNL.34.12.1582","article-title":"Drug-induced seizures: A 10-year experience","volume":"34","author":"Messing","year":"1984","journal-title":"Neurology"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03161033","article-title":"Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System","volume":"3","author":"Thundiyil","year":"2007","journal-title":"J Med Toxicol"},{"issue":"5 Suppl 2","key":"2020060307343868100_i2168-9709-7-6-235-b39","first-page":"S68","article-title":"Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations","volume":"53","author":"Alldredge","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b40","first-page":"262","article-title":"Treatment of bulimia with bupropion: a multicenter controlled trial","volume":"49","author":"Horne","year":"1988","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM199801013380104","article-title":"A population-based study of seizures after traumatic brain injuries","volume":"338","author":"Annegers","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/01.jcp.0000084023.22282.03","article-title":"Neurochemical and psychotropic effects of bupropion in healthy male subjects","volume":"23","author":"Gobbi","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b43","first-page":"256","article-title":"and bupropion: a review","volume":"50","author":"Seizures","year":"1989","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"2020060307343868100_i2168-9709-7-6-235-b44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ajem.2008.07.004","article-title":"Incidence and onset of delayed seizures after overdoses of extended-release bupropion","volume":"27","author":"Starr","year":"2009","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jemermed.2004.02.017","article-title":"Intentional bupropion overdoses","volume":"27","author":"Shepherd","year":"2004","journal-title":"J Emerg Med"},{"issue":"11","key":"2020060307343868100_i2168-9709-7-6-235-b46","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.clinthera.2005.11.011","article-title":"Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations","volume":"27","author":"Jefferson","year":"2005","journal-title":"Clin Ther"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b47","doi-asserted-by":"publisher","first-page":"248","DOI":"10.5152\/balkanmedj.2012.094","article-title":"Seizures after overdoses of bupropion intake","volume":"30","author":"Kara","year":"2013","journal-title":"Balkan Med J"},{"issue":"6","key":"2020060307343868100_i2168-9709-7-6-235-b48","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/emj.20.6.560","article-title":"Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose","volume":"20","author":"Jepsen","year":"2003","journal-title":"Emerg Med J"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4088\/JCP.v59n0705","article-title":"A prospective safety surveillance study for bupropion sustained-release in the treatment of depression","volume":"59","author":"Dunner","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2020060307343868100_i2168-9709-7-6-235-b50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","article-title":"Anticonvulsant hypersensitivity syndrome: incidence, prevention and management","volume":"21","author":"Knowles","year":"1999","journal-title":"Drug Saf"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b51","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b52","first-page":"272","article-title":"Anticonvulsant hypersensitivity syndrome (DRESS Syndrome): Report of 4 cases","volume":"16","author":"Meik","year":"2010","journal-title":"Dermatol Argent"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/epi4.12053","article-title":"DRESS syndrome: A case of cross-reactivity with lacosamide?","volume":"261916","author":"Fong","year":"2017","journal-title":"Epilepsia Open"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2710.2009.01081.x","article-title":"DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old Caucasian boy","volume":"35","author":"Pi\u00f1ana","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"9171","key":"2020060307343868100_i2168-9709-7-6-235-b58","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) \/ drug-induced hypersensitivity syndrome (DIHS): a review of current concepts","volume":"87","author":"Criado","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2133.2006.07332.x","article-title":"Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome","volume":"155","author":"Seishima","year":"2006","journal-title":"Br J Dermatol"},{"issue":"6982","key":"2020060307343868100_i2168-9709-7-6-235-b62","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"11","key":"2020060307343868100_i2168-9709-7-6-235-b63","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2020060307343868100_i2168-9709-7-6-235-b64","doi-asserted-by":"publisher","first-page":"CS57","DOI":"10.12659\/MSM.883198","article-title":"Treatment of DIHS\/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir \u2013 a hypothesis","volume":"18","author":"Moling","year":"2012","journal-title":"Med Sci Monit"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b65","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/clpt.2013.103","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing","volume":"94","author":"Leckband","year":"2013","journal-title":"Clin Pharmacol Ther"},{"author":"Novartis Pharmaceuticals Corporation","key":"2020060307343868100_i2168-9709-7-6-235-b66","article-title":"Tegretol (carbamazepine) tablet, chewable, suspension, extended release tablet"},{"issue":"5","key":"2020060307343868100_i2168-9709-7-6-235-b67","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1517\/14740338.2012.705828","article-title":"Anticonvulsant hypersensitivity syndrome: an update","volume":"11","author":"Knowles","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"2020060307343868100_i2168-9709-7-6-235-b68","first-page":"394","article-title":"Defining the drug hypersensitivity syndrome: pharmacological basis","author":"Shear","year":"1999","journal-title":"Dermatology at the millennium"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1017\/S1481803500012203","article-title":"Seizures induced by recreational abuse of bupropion tablets via nasal insufflation [abstract]","volume":"12","author":"Kim","year":"2010","journal-title":"CJEM"},{"issue":"6-7","key":"2020060307343868100_i2168-9709-7-6-235-b70","first-page":"759","article-title":"Jean Pastor MJ, Grob JJ. [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases]","volume":"128","author":"Richard","year":"2001","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5114\/pdia.2014.40930","article-title":"Severe skin complications in patients treated with antidepressants: a literature review","volume":"31","author":"Herstowska","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"2020060307343868100_i2168-9709-7-6-235-b72","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"12","key":"2020060307343868100_i2168-9709-7-6-235-b73","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/j.1528-1167.2008.01696.x","article-title":"Valproate teratogenicity and epilepsy syndrome","volume":"49","author":"Bromfield","year":"2008","journal-title":"Epilepsia"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b74","first-page":"56","article-title":"Adverse cutaneous reactions to psychopharmaceuticals","volume":"18","author":"Lamer","year":"2010","journal-title":"Acta Dermatovenerol Croat"},{"issue":"5","key":"2020060307343868100_i2168-9709-7-6-235-b75","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S1081-1206(10)61103-9","article-title":"Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents","volume":"97","author":"Seitz","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2020060307343868100_i2168-9709-7-6-235-b76","doi-asserted-by":"publisher","first-page":"853281","DOI":"10.1155\/2014\/853281","article-title":"Drug reaction with eosinophilia and systemic symptoms: DRESS following initiation of oxcarbazepine with elevated human herpesvirus-6 titer","volume":"2014","author":"Cornell","year":"2014","journal-title":"Case Rep Dermatol Med"},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","article-title":"Antiepileptic drugs in the treatment of psychiatric disorders","volume":"21","author":"Kaufman","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"5S","key":"2020060307343868100_i2168-9709-7-6-235-b78","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1525-5069(02)00501-7","article-title":"Psychiatric uses of antiepileptic treatments","volume":"3","author":"Boylan","year":"2002","journal-title":"Epilepsy Behav"},{"issue":"2","key":"2020060307343868100_i2168-9709-7-6-235-b79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yebeh.2013.08.024","article-title":"Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities","volume":"29","author":"Cavanna","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","article-title":"Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations","volume":"26","author":"Piedad","year":"2012","journal-title":"CNS Drugs"},{"issue":"5 Suppl 2","key":"2020060307343868100_i2168-9709-7-6-235-b81","first-page":"S53","article-title":"Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"issue":"11","key":"2020060307343868100_i2168-9709-7-6-235-b82","first-page":"HS15","article-title":"Behavioral side effects of antiepileptic drugs","volume":"38","author":"Thigpen","year":"2013","journal-title":"US Pharm"},{"key":"2020060307343868100_i2168-9709-7-6-235-b83","unstructured":"Lexicomp Online\u00ae. Lexi-Drugs\u00ae. Hudson (OH): Lexi-Comp, Inc.; August 24, 2017."},{"issue":"1","key":"2020060307343868100_i2168-9709-7-6-235-b84","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"2020060307343868100_i2168-9709-7-6-235-b85","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1055\/s-0028-1111776","article-title":"[Psychic disorders in epilepsy. Clinical and electroencephalographic research]","volume":"87","author":"Landolt","year":"1962","journal-title":"Dtsch Med Wochenschr"},{"issue":"10","key":"2020060307343868100_i2168-9709-7-6-235-b86","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1017\/S1092852900010403","article-title":"Beyond monoamines: glutamatergic function in mood disorder [abstract]","volume":"10","author":"Kugaya","year":"2005","journal-title":"CNS Spectr"},{"issue":"9","key":"2020060307343868100_i2168-9709-7-6-235-b87","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"author":"US Food and Drug Administration","key":"2020060307343868100_i2168-9709-7-6-235-b88","article-title":"Suicidal behavior and ideation and antiepileptic drugs"},{"key":"2020060307343868100_i2168-9709-7-6-235-b89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/DHPS.S13225","article-title":"Antiepileptic drugs and suicidality","volume":"2","author":"Britton","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"2020060307343868100_i2168-9709-7-6-235-b90","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ebcr.2015.07.004","article-title":"Levetiracetam-induced rage and suicidality: two case reports and review of literature","volume":"4","author":"Molokwu","year":"2015","journal-title":"Epilepsy Behav Case Reports"},{"issue":"suppl 7","key":"2020060307343868100_i2168-9709-7-6-235-b91","first-page":"259","article-title":"Possible association of behavioral disturbances with levetiracetam: report of a case series","volume":"42","author":"Rickles","year":"2001","journal-title":"Epilepsia"},{"issue":"4","key":"2020060307343868100_i2168-9709-7-6-235-b92","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.yebeh.2012.01.012","article-title":"Impact of antiepileptic drugs on genesis of psychosis","volume":"23","author":"Noguchi","year":"2012","journal-title":"Epilepsy Behav"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/6\/235\/2096434\/mhc_2017_11_235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/6\/235\/2096434\/mhc_2017_11_235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:14Z","timestamp":1731687794000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/6\/article-p235.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.11.235","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}